PCI Pharma Services Welcomes Two New Business Development Executives to Support its Growing US Market

Leading pharmaceutical outsourcing services provider PCI Pharma Services has announced the appointment of Sue Ritchie and Fred Schulze to its US sales team, with business development responsibility for PCI’s expanding global development and manufacturing capability.

This content was submitted directly to this website by the supplier.

Sue and Fred join PCI Pharma Services (PCI) to develop clients across the full suite of PCI’s drug development services spanning analytical testing; formulation development; and clinical and commercial manufacturing, including special expertise in contained manufacturing of highly potent compounds. These services are complemented by PCI’s extensive services in clinical trial packaging and labeling, global logistical services for clinical trial supplies, as well as commercial packaging services. Together, Sue and Fred bring to PCI significant specialist experience in solution selling of pharmaceutical development and manufacturing services to support PCI’s client base in the US.

Sue joins PCI Pharma Services with an extensive background in the pharmaceutical industry, most recently with Delavau. She has held previous positions with Johnson & Johnson and King Pharmaceuticals, among others.

Fred has 30 years of broad experience in the pharmaceutical services market, most recently serving as Vice President of Sales and Marketing at Coating Place Inc. and previously working with Cardinal Health.

Commenting on the appointments, Rob Jones, Executive Director of Business Development at PCI, said: “We are delighted to welcome Sue and Fred to the PCI team. They bring extensive experience in selling services within the USA market to our client base of pharmaceutical and biotech companies which will greatly support our continued growth ambitions.”

PCI has announced several key investments in its manufacturing operations recently, including the installation of a contained Gerteis roller compactor; installation of contained Xcelodose® machines; expanded commercial manufacturing capacity; as well as the most recent announcement of a facilities expansion to be undertaken this year.


Companies in this article
Videos from PCI Pharma ServicesView all videos
Compliance Adherence
Asia Pacific Studies
PotentCompounds 1
More in Home